Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma

OBJECTIVE: This dose-escalation part of an ongoing Phase I study assessed the tolerability, safety and pharmacokinetics of mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). METHODS: Mosunetuzumab was administered intravenously, with step-up dosing in a 3 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Munakata, Wataru, Izutsu, Koji, Mishima, Yuko, Nagai, Hirokazu, Ishihara, Yuko, Suzumiya, Junji, Kanakura, Yuzuru, Nanki, Toshihiro, Miyake, Takeshi, Kawasaki, Atsuko, Yoshinaga, Tatsuya, Ishizawa, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550201/
https://www.ncbi.nlm.nih.gov/pubmed/37486002
http://dx.doi.org/10.1093/jjco/hyad082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550201/
https://www.ncbi.nlm.nih.gov/pubmed/37486002
http://dx.doi.org/10.1093/jjco/hyad082

Ejemplares similares